Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 double-blind trial of nirmatrelvir + ritonavir versus placebo in low-risk nonhospitalized adults with COVID-19
jRCT2031210274Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing nirmatrelvir + ritonavir with placebo (2 arms). Primary endpoint: Time to sustained alleviation of all targeted COVID-19 signs/symptoms. Started Aug 2021; status: completed.
02
Drugs
Nirmatrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210274.